CCR5 and pancreatic ductal adenocarcinoma: Moreover, combining CXCR4 or CCR5 antagonists with anti-PD1 immunotherapy has shown promising results in colorectal cancer, renal cell carcinoma, and pancreatic ductal adenocarcinoma, including clinical trials [77,103,104,105,106,108].